TR200101256T2 - DNA ile aşılamada geliştirmeler - Google Patents

DNA ile aşılamada geliştirmeler

Info

Publication number
TR200101256T2
TR200101256T2 TR2001/01256T TR200101256T TR200101256T2 TR 200101256 T2 TR200101256 T2 TR 200101256T2 TR 2001/01256 T TR2001/01256 T TR 2001/01256T TR 200101256 T TR200101256 T TR 200101256T TR 200101256 T2 TR200101256 T2 TR 200101256T2
Authority
TR
Turkey
Prior art keywords
enhancements
mammal
compound
disease state
antigenic peptide
Prior art date
Application number
TR2001/01256T
Other languages
English (en)
Inventor
Charo Jehad
Kiessling Rolf
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200101256T2 publication Critical patent/TR200101256T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Bir memeliyi bir hastalik durumuna karsi asilamak için bir yöntem olup, bu yöntem sözü edilen memeliye, uygun bir vektör içinde, hastalik durumu ile iliskili bir antijenik peptid kodlayan bir nükleotid dizisi verilmesini; buna ilaveten sözü edilen memeliye, antijenik peptid tarafindan baslatilan hem hümoral hem de hücresel bagisiklik tepkilerini artiran bir bilesik verilmesini içerir; bu bilesik, burada verilen bir listeden seçilir ve bu bilesik tercihan Tucaresol veya uygun durumlarda, bunun fizyolojik açidan kabul edilebilir bir tuzu veya esteridir.
TR2001/01256T 1998-08-26 1999-08-25 DNA ile aşılamada geliştirmeler TR200101256T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818627.3A GB9818627D0 (en) 1998-08-26 1998-08-26 Improvements in dva vaccination

Publications (1)

Publication Number Publication Date
TR200101256T2 true TR200101256T2 (tr) 2001-10-22

Family

ID=10837881

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01256T TR200101256T2 (tr) 1998-08-26 1999-08-25 DNA ile aşılamada geliştirmeler

Country Status (22)

Country Link
US (1) US7074770B1 (tr)
EP (1) EP1107785B1 (tr)
JP (1) JP2002523469A (tr)
KR (1) KR20010072983A (tr)
CN (1) CN1326358A (tr)
AT (1) ATE411043T1 (tr)
AU (1) AU747643B2 (tr)
BR (1) BR9913323A (tr)
CA (1) CA2341544A1 (tr)
CZ (1) CZ2001717A3 (tr)
DE (1) DE69939747D1 (tr)
ES (1) ES2313791T3 (tr)
GB (1) GB9818627D0 (tr)
HU (1) HUP0103214A3 (tr)
IL (1) IL141623A0 (tr)
NO (1) NO20010922L (tr)
NZ (1) NZ510206A (tr)
OA (1) OA11644A (tr)
PL (1) PL346299A1 (tr)
TR (1) TR200101256T2 (tr)
WO (1) WO2000012121A1 (tr)
ZA (1) ZA200101539B (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP1227840B1 (en) * 1999-11-03 2007-10-03 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
AU2001251491A1 (en) * 2000-04-11 2001-10-23 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
CN100567242C (zh) * 2003-06-27 2009-12-09 协和发酵麒麟株式会社 Hsp90家族蛋白质阻断剂
CN100415876C (zh) * 2003-09-05 2008-09-03 杭州浙大康泰生物技术有限公司 艾滋病重组腺病毒疫苗
JP5785559B2 (ja) 2009-12-16 2015-09-30 クロンテック ファーマ アーベー 注射針および注射装置
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
PT2797416T (pt) * 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
US10946096B2 (en) 2014-02-26 2021-03-16 The Board Of Regents Of The University Of Texas System Nitrobenzaldehyde proton release for manipulation of cellular acidosis
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
US11267807B2 (en) * 2015-10-28 2022-03-08 The Brigham And Women's Hospital, Inc. Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232238B (zh) * 2018-08-29 2022-05-17 北京勤邦生物技术有限公司 吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
JP2023539352A (ja) * 2020-08-26 2023-09-13 ガートルード・バイオメディカル・ピーティーワイ・リミテッド 抗ウイルスｓｏｘ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
DE69306545T2 (de) * 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit

Also Published As

Publication number Publication date
NZ510206A (en) 2003-08-29
HUP0103214A3 (en) 2003-10-28
CN1326358A (zh) 2001-12-12
KR20010072983A (ko) 2001-07-31
US7074770B1 (en) 2006-07-11
IL141623A0 (en) 2002-03-10
PL346299A1 (en) 2002-01-28
CZ2001717A3 (cs) 2001-10-17
NO20010922D0 (no) 2001-02-23
AU747643B2 (en) 2002-05-16
GB9818627D0 (en) 1998-10-21
AU5740299A (en) 2000-03-21
HUP0103214A2 (hu) 2001-12-28
ZA200101539B (en) 2002-02-25
WO2000012121A1 (en) 2000-03-09
ATE411043T1 (de) 2008-10-15
CA2341544A1 (en) 2000-03-09
EP1107785B1 (en) 2008-10-15
NO20010922L (no) 2001-04-23
EP1107785A1 (en) 2001-06-20
BR9913323A (pt) 2001-12-04
DE69939747D1 (de) 2008-11-27
ES2313791T3 (es) 2009-03-01
OA11644A (en) 2004-11-22
JP2002523469A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ514887A (en) IBD-associated microbial antigens and methods of using same
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
HK1039749A1 (en) Use of expressions of ctl and t-helper lymph cellsin vaccination
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
BR9913446A (pt) Produtos de aglicona e métodos de uso
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
EP1242049A4 (en) HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINES
EP1090294A4 (en) METHOD FOR DETERMINING THE PRESENCE OF CANCER IN A SAMPLE BY DETECTING THE EXPRESSION OF A SSX GENE AND PEPTIDES DERIVED FROM SSX OR NY-ESO-1
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
HK1048819A1 (en) Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
MXPA03010261A (es) Metodos para tratar cancer.
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug